Antengene (HKSE:06996) Net Margin % : 7,694.22% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Antengene Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Antengene's Net Income for the six months ended in Dec. 2023 was HK$-396.48 Mil. Antengene's Revenue for the six months ended in Dec. 2023 was HK$-5.15 Mil. Therefore, Antengene's net margin for the quarter that ended in Dec. 2023 was 7,694.22%.

The historical rank and industry rank for Antengene's Net Margin % or its related term are showing as below:

HKSE:06996' s Net Margin % Range Over the Past 10 Years
Min: -2278.58 Med: -863.5 Max: -375.61
Current: -863.5

HKSE:06996's Net Margin % is ranked worse than
71.86% of 1020 companies
in the Biotechnology industry
Industry Median: -152.785 vs HKSE:06996: -863.50

Antengene Net Margin % Historical Data

The historical data trend for Antengene's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Net Margin % Chart

Antengene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-2,278.58

-375.61

-863.50

Antengene Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	Get a 7-Day Free Trial						-1,468.70	-267.72	-430.44	-303.67	7,694.22

Competitive Comparison of Antengene's Net Margin %

For the Biotechnology subindustry, Antengene's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antengene's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's Net Margin % distribution charts can be found below:

* The bar in red indicates where Antengene's Net Margin % falls into.

Antengene Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Antengene's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-635.686	/	73.617
	=	-863.50 %

Antengene's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-396.483	/	-5.153
	=	7,694.22 %

Antengene (HKSE:06996) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Antengene Net Margin % Related Terms

Thank you for viewing the detailed overview of Antengene's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Antengene (HKSE:06996) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN

Website

https://www.antengene.com

Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in China and other regions.

Executives

Jay Mei 2023 Grat	2201 Interest of corporation controlled by you
Mei Jay	2201 Interest of corporation controlled by you
Begonia Investment Ltd.	2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Fountainvest China Capital Partners Gp3 Ltd.	2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p.	2201 Interest of corporation controlled by you
Fmr Llc	2201 Interest of corporation controlled by you
Fidelity Investment Trust	2101 Beneficial owner
Jay Mei 2020 Grat	2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene (HKSE:06996) Headlines

No Headlines